Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 1 8Phase 1/2 2Phase NA 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 41Gastrointestinal 13Head & Neck 7CNS 7Sarcoma 5Genitourinary 4Gynecologic 2Dermatologic 2Breast 2Tumor-Agnostic 1Other neoplasm 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Breast Neoplasms, Male 1

Interventions

Trastuzumab 72Paclitaxel 63Cyclophosphamide 56pembrolizumab 52Fulvestrant 42Carboplatin 39Capecitabine 37Docetaxel 32Letrozole 27Doxorubicin 23palbociclib 21pertuzumab 20Nivolumab 18eribulin 17abemaciclib 17ribociclib 16Gemcitabine 16130-nm albumin-bound paclitaxel 16durvalumab 15Everolimus 15Albumin-Bound Paclitaxel 15sacituzumab govitecan 14Lapatinib 14Filgrastim 14fludarabine 13exemestane 13Taxes 13Bevacizumab 13Cisplatin 12olaparib 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Erlotinib Hydrochloride × Breast × Clear all
NCT00033514 2020-10-08

Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression

Jonsson Comprehensive Cancer Center

Phase 1/2 Completed
27 enrolled 12 charts
Breast

Breast Neoplasms

NCT00834678 2018-04-17

Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

Ohio State University Comprehensive Cancer Center

Phase 1/2 Completed
11 enrolled 16 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡